Clinical trial NCT00703638 (phase 1, status: completed)
Conditions: breast cancer, colorectal cancer, head and neck cancer, lung cancer, mesothelioma, pancreatic cancer, prostate cancer, sarcoma
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60, C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2, C76.0, C47.0, C49.0, C77.0, D17.0, D21.0, D36.11, C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2, C45.9, C45.0, C45.1, C45.2, C45.7, C25.3, C61, D29.1, D40.0, Z15.03, Z80.42, Z85.46, Z12.5, C96.A, C46.9, C96.22, C46.0, C46.2, C92.31, C92.32
Drugs: cisplatin, pemetrexed disodium, sorafenib
SMILES: [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, [H][C@@](CCC(O)=O)(NC(=O)C1=CC=C(CCC2=CNC3=C2C(O)=NC(=N)N3)C=C1)C(O)=O, CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1
Eligibility criteria:

        Inclusion criteria:

          -  Histologic or cytologic diagnosis of advanced non-hematologic malignancy (except
             squamous cell of the lung) including, but not limited to breast, lung, colon,
             pancreatic, prostate, head and neck, or sarcoma

          -  Must have failed or become intolerant to prior standard therapy and is no longer
             likely to respond to such therapy except for patients diagnosed with mesothelioma.
             Mesothelioma patients may be enrolled with no prior therapy requirements since
             cisplatin and pemetrexed in combination is the current standard of care 1st line
             therapy.

          -  At least 21 days must have passed from previous systemic therapy (at least 6 weeks for
             prior bevacizumab) and the patient must have recovered from the all toxic effects of
             previous treatment prior to study enrollment. Prior treatment with cisplatin and/or
             pemetrexed is allowed, but at least 3 months must have passed since the last dose.
             Prior treatment with sorafenib is not allowed.

          -  Prior radiation therapy is allowed except to the whole pelvis. At least 14 days from
             last radiation therapy treatment and must have recovered from the acute toxic effects
             prior to study enrollment.

          -  Measurable or non-measurable disease as defined by Response Evaluation Criteria in
             Solid Tumors (RECIST) criteria

          -  Eastern Cooperative Oncology Group (ECOG) Performance status of 0 to 2

          -  18 years of age and older

          -  Adequate organ function within 7 days of study enrollment including the following:

               -  Adequate bone marrow reserve: absolute neutrophil count (ANC) ≥ 1.5 x 10^9/L;
                  platelets ≥100 x 10^9/L; hemoglobin ≥ 9 g/dL

               -  Hepatic: bilirubin ≤1.5 times the upper limit of normal (× ULN); alkaline
                  phosphatase (ALP), aspartate transaminase (AST) and alanine transaminase (ALT) ≤
                  3.0 × ULN (ALP, AST, and ALT ≤ 5× ULN is acceptable if liver has tumor
                  involvement)

               -  Renal: serum creatinine ≤ 1.5 and calculated creatinine clearance > 45.

        The creatinine clearance is determined by the Cockcroft-Gault formula:

          -  Males: cr cl (mL)/min) = weight (kg) x (140-age)divided by 72 x serum creatinine
             (mg/dL)

          -  Females: cr cl (mL)/min) = weight (kg) x (140-age) x 0.85 divided by 72 x serum
             creatinine (mg/dL)

               -  Coagulation: INR < 1.5 or a PT/PTT within normal limits

          -  Patients receiving anti-coagulation treatment with an agent such as warfarin or
             heparin may be allowed to participate. For patients on warfarin, the INR should be
             measured prior to initiation of sorafenib and monitored at least weekly, or as defined
             by the local standard of care, until INR is stable.

               -  Women of childbearing potential and sexually active males are required to use an
                  effective method of contraception (barrier method of birth control) during the
                  study and for 2 weeks after the last dose of sorafenib.

               -  Must be able to take folic acid and vitamin B12.

               -  Must be able and willing to interrupt aspirin or other nonsteroidal
                  antiinflammatory agents for a 5 day period (8 day period for long acting agents
                  such as piroxicam) prior at the time of each pemetrexed administration.

               -  Must be able to take oral medications without crushing, dissolving, or chewing
                  tablets.

               -  Voluntary written informed consent before performance of any study related
                  procedure not part of normal medical care, with the understanding that consent
                  may be withdrawn by the subject at any time without prejudice to future medical
                  care.

        Exclusion Criteria:

          -  Squamous cell of the lung

          -  Pregnant (positive pregnancy test) or breast-feeding. Pemetrexed, cisplatin and
             sorafenib are pregnancy category D - clear evidence of risk in pregnancy. Women of
             child bearing potential must have a negative serum or urine pregnancy test within 7
             days of prior to the start of treatment. Pregnancy testing is not required for
             postmenopausal or surgically sterilized women.

          -  Cardiac disease: Congestive heart failure > class II New York Heart Association
             Classification (NYHA). Patients must not have unstable angina (anginal symptoms at
             rest) or new onset angina (began within the last 3 months) or myocardial infarction
             within the past 6 months.

          -  Symptomatic or active brain metastases. Patients with neurological symptoms or
             previously treated CNS metastases must undergo a CT scan/MRI of the brain within 14
             days of study enrollment to rule-out brain metastasis.

          -  The presence of clinically significant third space fluid such as pleural effusion or
             ascites. Patients in whom the third space fluid can be completely drained may be
             enrolled.

          -  Cardiac ventricular arrhythmias requiring anti-arrhythmic therapy

          -  Uncontrolled hypertension defined as systolic blood pressure > 150 mmHg or diastolic
             pressure > 90 mmHg, despite optimal medical management

          -  Known or suspected allergy to sorafenib, pemetrexed, cisplatin or any agent given in
             the course of this trial

          -  Known human immunodeficiency virus (HIV) infection or chronic Hepatitis B or C

          -  Patients must not have a second primary malignancy except in situ carcinoma of the
             cervix or breast or other in situ malignancies or adequately treated basal cell
             carcinoma of the skin or other malignancy treated at least 3 years previously with no
             evidence of recurrence

          -  Active clinically serious infection > Common Toxicity Criteria for Adverse Events
             (CTCAE) Grade 2

          -  Thrombolic or embolic events such as a cerebrovascular accident including transient
             ischemic attacks within the past 6 months

          -  Pulmonary hemorrhage/bleeding event ≥ CTCAE Grade 2 within 4 weeks of first dose of
             study drug

          -  Any other hemorrhage/bleeding event ≥ CTCAE Grade 3 within 4 weeks of first dose of
             study drug

          -  Serious non-healing wound, ulcer, or bone fracture

          -  Evidence or history of bleeding diathesis or coagulopathy

          -  Peripheral neuropathy ≥ CTCAE Grade 2

          -  Major surgery, open biopsy or significant traumatic injury within 4 weeks of first
             study drug

          -  Use of St. John's Wort or rifampin (rifampicin)

          -  Any condition that impairs patient's ability to swallow whole pills

          -  Any malabsorption problem